



**PROHIBITION OF SALES TO EEA RETAIL INVESTORS:** The Securities are not intended to be offered, sold or otherwise made available to and may not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA"). For these purposes, retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU on Markets in Financial Instruments (as may be amended, varied or replaced from time to time) ("**MiFID II**"); (ii) a customer within the meaning of Directive (EU) 2016/97 (the "**Insurance Distribution Directive**"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in the Prospectus Regulation. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "**PRIIPs Regulation**") for offering or selling the Securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling such Securities or otherwise making them available to any retail investors in the EEA may be unlawful under the PRIIPs Regulation.

**PROHIBITION OF SALES TO UK RETAIL INVESTORS:** The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom ("**UK**"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("**EUWA**"); (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000, as amended (the "**FSMA**") and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA. Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the "**UK PRIIPs Regulation**") for offering or selling the Securities or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling such Securities or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

**Final Terms dated 27 July 2021**

**Credit Suisse AG, London Branch**

**Legal Entity Identifier (LEI): ANGGYXNX0JLX3X63JN86**

**Trigger Yield Equity-linked Securities due July 2023**

linked to **Sarepta Therapeutics Inc, BioMarin Pharmaceutical Inc, Vertex Pharmaceuticals Inc and Neurocrine Biosciences Inc** (the "**Securities**")

Series SPLB2021-1Y0D

ISIN: XS2365553309

issued pursuant to the Trigger Redeemable and Phoenix Securities Base Prospectus

as part of the **Structured Products Programme for the issuance of Notes, Certificates and Warrants**

## **PART A - CONTRACTUAL TERMS**

Terms used herein shall be deemed to be defined as such in the General Conditions, the Product Conditions and the applicable Asset Terms (as may be amended and/or supplemented up to, and including, the Issue Date), set forth in the Securities Note dated 9 July 2021, as supplemented by any supplements up to, and including, the later of the Issue Date and the date of listing of the Securities (together, the "**Securities Note**") which, together with the Registration Document dated 11 June 2021, as supplemented on 20 July 2021 and by any further supplements up to, and including, the later of the Issue Date and the date of listing of the Securities (together, the "**Registration Document**"), constitutes a base prospectus for the purposes of the Prospectus Regulation (the "**Base Prospectus**"). This document constitutes the Final Terms of the Securities described herein for the purposes of Article 8(4) of the Prospectus Regulation and must be read in conjunction with such Base Prospectus in order to obtain all the relevant information. A summary of the Securities is annexed to these Final Terms. Copies of the documents comprising the Base Prospectus may be obtained from the website of Credit Suisse (<https://derivative.credit-suisse.com>).

These Final Terms comprise the final terms for the issue and admission to trading on the regulated market of the Luxembourg Stock Exchange of the Securities. The Final Terms will be available on the website of Credit Suisse (<https://derivative.credit-suisse.com>) and the website of the Luxembourg Stock Exchange ([www.bourse.lu](http://www.bourse.lu)).

1	Series Number:	SPLB2021-1Y0D
2	Tranche Number:	Not Applicable
3	Applicable General Terms and Conditions:	General Note Conditions
4	Type of Security:	Trigger Yield Securities
5	Settlement Currency:	United States Dollar (" <b>USD</b> ")
6	Institutional:	Not Applicable

<b>PROVISIONS RELATING TO NOTES AND CERTIFICATES</b>	Applicable
7 Aggregate Nominal Amount:	
(i) Series:	USD 1,131,000.00
(ii) Tranche:	Not Applicable
8 Issue Price:	100% of the Aggregate Nominal Amount
9 Specified Denomination:	USD 1,000.00
10 Minimum Transferable Number of Securities:	Not Applicable
11 Transferable Number of Securities:	Not Applicable
12 Minimum Trading Lot:	Not Applicable
13 Issue Date:	28 July 2021
14 Maturity Date:	5 Currency Business Days following the Final Fixing Date or, if such date falls on different dates for different Underlying Assets, the latest of such dates to occur (expected to be 28 July 2023)
15 Coupon Basis:	Applicable: Fixed Rate Provisions
16 Redemption/Payment Basis:	Equity-linked
17 Put/Call Options:	Not Applicable

**PROVISIONS RELATING TO WARRANTS** Not Applicable

*(Paragraphs 18 to 28 have been intentionally deleted)*

**PROVISIONS RELATING TO COUPON AMOUNTS**

29 Fixed Rate Provisions (General Note Condition 4 or General Certificate Condition 4):	Applicable
(i) Rate(s) of Interest:	Not Applicable
(ii) Interest Commencement Date:	Issue Date
(iii) Interest Payment Date(s):	Each of 28 October 2021, 28 January 2022, 28 April 2022, 28 July 2022, 28 October 2022, 30 January 2023, 28 April 2023 and 28 July 2023
(iv) Interest Period:	Not Applicable
(v) Business Day Convention:	Not Applicable
(vi) Interest Amount(s) per Security:	An amount equal to 2.25% of the Nominal Amount
(vii) Day Count Fraction:	Not Applicable
(viii) Determination Date(s):	Not Applicable
(ix) Trade Date:	Not Applicable
30 Floating Rate Provisions (General Note Condition 4 or General Certificate Condition 4):	Not Applicable
31 Premium Provisions (General Note Condition 4 or General Certificate Condition 4):	Not Applicable
32 Other Coupon Provisions (Product Condition 2):	Not Applicable

**PROVISIONS RELATING TO REDEMPTION/SETTLEMENT**

33 Redemption Amount or (in the case of Warrants) Settlement Amount (Product Condition 3):	Worst of Phoenix
(i) Redemption Option Percentage:	Applicable: 100 per cent.
(ii) Redemption Performance:	Not Applicable
(iii) Redemption Amount Cap/Floor:	Applicable
- Redemption Amount Cap 1:	An amount equal to 100 per cent. of the Nominal Amount
- Redemption Amount Floor 1:	Not Applicable

	- Redemption Amount Cap 2:	Not Applicable
	- Redemption Amount Floor 2:	Not Applicable
(iv)	Redemption Strike Price:	In respect of an Underlying Asset, an amount equal to 70% of the Strike Price of such Underlying Asset
(v)	Redemption FX Adjustment:	Not Applicable
(vi)	PPT:	Not Applicable
(vii)	Strike:	Not Applicable
(viii)	Nth (for the purposes of determining the Worst Performing Underlying Asset):	1st lowest (i.e. the lowest) as specified in Product Condition 1
34	Initial Setting Date:	21 July 2021
35	Initial Averaging Dates:	Not Applicable
36	Final Fixing Date:	21 July 2023
37	Averaging Dates:	Not Applicable
38	Final Price:	In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Final Fixing Date
	(i) Final Price Cap:	Not Applicable
	(ii) Final Price Floor:	Not Applicable
39	Strike Price:	In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Initial Setting Date
	(i) Strike Cap:	Not Applicable
	(ii) Strike Floor:	Not Applicable
40	Knock-in Provisions:	Applicable
	(i) Knock-in Event:	On the Knock-in Observation Date, the Level (with regard to the Valuation Time) of any Underlying Asset is below the Knock-in Barrier of such Underlying Asset
	(ii) Knock-in Barrier:	In respect of the Knock-in Observation Date and an Underlying Asset, an amount equal to 70% of the Strike Price of such Underlying Asset
	(iii) Knock-in Observation Date(s):	In respect of an Underlying Asset, 21 July 2023
	(iv) Knock-in Observation Date subject to Valuation Date adjustment:	Valuation Date adjustment applicable in respect of the Knock-in Observation Date
	(v) Knock-in Observation Period:	Not Applicable
	(vi) Knock-in Fixing Price:	Not Applicable
	(vii) Redemption Participation:	Not Applicable
	(viii) Floor:	Not Applicable
	(ix) Knock-out Event Override Condition:	Not Applicable
41	Knock-out Provisions:	Not Applicable
42	Trigger Redemption (Product Condition 3(c)):	Applicable
	(i) Trigger Event:	On any Trigger Barrier Observation Date, the Level (with regard to the Valuation Time) of each Underlying Asset is at or above the Trigger Barrier of such Underlying Asset
	(ii) Trigger Barrier Redemption Date(s):	In respect of a Trigger Barrier Observation Date, as specified in the table below in respect of such Trigger Barrier Observation Date
	(iii) Trigger Barrier Redemption Amount:	In respect of a Trigger Barrier Redemption Date, as specified in the table below in respect of such Trigger Barrier Redemption Date
	(iv) Trigger Barrier:	In respect of a Trigger Barrier Observation Date and an Underlying Asset, as specified in the table below in respect of such Trigger Barrier Observation Date
	(v) Trigger Barrier Observation Date(s):	In respect of an Underlying Asset and a Trigger Barrier Redemption Date, as specified in the table below in respect of such Trigger Barrier Redemption Date

- (vi) Trigger Barrier Observation Date subject to Valuation Date adjustment: Valuation Date adjustment applicable in respect of all Trigger Barrier Observation Dates
- (vii) Trigger Barrier Observation Period(s): Not Applicable

	Trigger Barrier Observation Date <sub>n</sub>	Trigger Barrier <sub>n</sub>	Trigger Barrier Redemption Amount <sub>n</sub>	Trigger Barrier Redemption Date <sub>n</sub>
1	21 January 2022	An amount equal to 97% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
2	21 April 2022	An amount equal to 94% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
3	21 July 2022	An amount equal to 91% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
4	21 October 2022	An amount equal to 88% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
5	21 January 2023	An amount equal to 85% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
6	21 April 2023	An amount equal to 82% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
7	21 July 2023	An amount equal to 79% of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event

- (viii) Knock-in Event Override Condition: Not Applicable
- (ix) Trigger Barrier Fixing Price: Not Applicable
- (x) Trigger Coupon Override Condition: Not Applicable
- (xi) Trigger Knock-out Barrier: Not Applicable
- (xii) Trigger Knock-out Event: Not Applicable
- (xiii) Trigger Knock-out Observation Period Start Date(s): Not Applicable
- (xiv) Trigger Knock-out Observation Period End Date(s): Not Applicable
- 43 Lock-in Redemption: Not Applicable
- 44 Single Factor Trigger Redeemable (Step-Up) / Single Factor Trigger Redeemable (Star) / Worst of Trigger Redeemable (Step-Up) / Worst of Trigger Redeemable (Star): Not Applicable
- 45 Knock-in Put Spread: Not Applicable
- 46 Details relating to Instalment Securities: Not Applicable
- 47 Physical Settlement Provisions (Product Condition 4): Not Applicable
- 48 Put Option: Not Applicable
- 49 Call Option: Not Applicable
- 50 Unscheduled Termination Amount:
- (i) Unscheduled Termination at Par: Not Applicable
- (ii) Minimum Payment Amount: Not Applicable
- (iii) Deduction for Hedge Costs: Not Applicable
- 51 Payment Disruption: Not Applicable

52 Interest and Currency Rate Additional Disruption Event: Not Applicable

53 Dividend Adjusted Performance: Not Applicable

**UNDERLYING ASSET(S)**

54 List of Underlying Asset(s): Applicable

<b>i</b>	<b>Underlying Asset:</b>	<b>Weight:</b>	<b>Composite:</b>
1	The ordinary shares of Sarepta Therapeutics Inc (the " <b>Sarepta Therapeutics Inc Shares</b> ")	Not Applicable	Not Applicable
2	The ordinary shares of BioMarin Pharmaceutical Inc (the " <b>BioMarin Pharmaceutical Inc Shares</b> ")	Not Applicable	Not Applicable
3	The ordinary shares of Vertex Pharmaceuticals Inc (the " <b>Vertex Pharmaceuticals Inc Shares</b> ")	Not Applicable	Not Applicable
4	The ordinary shares of Neurocrine Biosciences Inc (the " <b>Neurocrine Biosciences Inc Shares</b> ")	Not Applicable	Not Applicable

55 Equity-linked Securities: Applicable

Single Share, Share Basket or Multi-Asset Basket: Share Basket

- 1
- (i) Share Issuer: Sarepta Therapeutics Inc
  - (ii) Share: The Sarepta Therapeutics Inc Shares
  - (iii) ISIN: US8036071004
  - (iv) Bloomberg Code: SRPT UW Equity
  - (v) Information Source: <https://www.nasdaq.com>
  - (vi) Exchange: NASDAQ
  - (vii) Related Exchange: NASDAQ
  - (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1
  - (ix) Adjustment basis for Share Basket and Reference Dates: In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual
  - (x) Adjustment basis for Share Basket and Averaging Reference Dates: Not Applicable
  - (xi) Trade Date: 21 July 2021
  - (xii) Jurisdictional Event: Not Applicable
  - (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable
  - (xiv) Share Substitution: Applicable
  - (xv) Additional Disruption Events:
    - (a) Change in Law: Change in Law Option 1 Applicable
    - (b) Change of Exchange: Applicable
    - (c) Foreign Ownership Event: Not Applicable
    - (d) FX Disruption: Not Applicable
    - (e) Insolvency Filing: Applicable
    - (f) Hedging Disruption: Applicable
    - (g) Increased Cost of Hedging: Not Applicable
    - (h) Loss of Stock Borrow: Not Applicable
    - (i) Increased Cost of Stock Borrow: Not Applicable
  - (xvi) Dividend Adjusted Performance: Not Applicable
- 2
- (i) Share Issuer: BioMarin Pharmaceutical Inc

	(ii)	Share:	The BioMarin Pharmaceutical Inc Shares
	(iii)	ISIN:	US09061G1013
	(iv)	Bloomberg Code:	BMRN UW Equity
	(v)	Information Source:	<a href="http://www.nasdaq.com">http://www.nasdaq.com</a>
	(vi)	Exchange:	NASDAQ
	(vii)	Related Exchange:	All Exchanges
	(viii)	Maximum Days of Disruption:	Eight Scheduled Trading Days as specified in Asset Term 1
	(ix)	Adjustment basis for Share Basket and Reference Dates:	In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual
	(x)	Adjustment basis for Share Basket and Averaging Reference Dates:	Not Applicable
	(xi)	Trade Date:	21 July 2021
	(xii)	Jurisdictional Event:	Not Applicable
	(xiii)	Jurisdictional Event Jurisdiction(s):	Not Applicable
	(xiv)	Share Substitution:	Applicable
	(xv)	Additional Disruption Events:	
		(a) Change in Law:	Change in Law Option 1 Applicable
		(b) Change of Exchange:	Applicable
		(c) Foreign Ownership Event:	Not Applicable
		(d) FX Disruption:	Not Applicable
		(e) Insolvency Filing:	Applicable
		(f) Hedging Disruption:	Applicable
		(g) Increased Cost of Hedging:	Not Applicable
		(h) Loss of Stock Borrow:	Not Applicable
		(i) Increased Cost of Stock Borrow:	Not Applicable
	(xvi)	Dividend Adjusted Performance:	Not Applicable
3	(i)	Share Issuer:	Vertex Pharmaceuticals Inc
	(ii)	Share:	The Vertex Pharmaceuticals Inc Shares
	(iii)	ISIN:	US92532F1003
	(iv)	Bloomberg Code:	VRTX UW Equity
	(v)	Information Source:	<a href="http://www.nasdaq.com">http://www.nasdaq.com</a>
	(vi)	Exchange:	NASDAQ
	(vii)	Related Exchange:	All Exchanges
	(viii)	Maximum Days of Disruption:	Eight Scheduled Trading Days as specified in Asset Term 1
	(ix)	Adjustment basis for Share Basket and Reference Dates:	In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual
	(x)	Adjustment basis for Share Basket and Averaging Reference Dates:	Not Applicable
	(xi)	Trade Date:	21 July 2021
	(xii)	Jurisdictional Event:	Not Applicable
	(xiii)	Jurisdictional Event Jurisdiction(s):	Not Applicable
	(xiv)	Share Substitution:	Applicable

	(xv) Additional Disruption Events:	
	(a) Change in Law:	Change in Law Option 1 Applicable
	(b) Change of Exchange:	Applicable
	(c) Foreign Ownership Event:	Not Applicable
	(d) FX Disruption:	Not Applicable
	(e) Insolvency Filing:	Applicable
	(f) Hedging Disruption:	Applicable
	(g) Increased Cost of Hedging:	Not Applicable
	(h) Loss of Stock Borrow:	Not Applicable
	(i) Increased Cost of Stock Borrow:	Not Applicable
	(xvi) Dividend Adjusted Performance:	Not Applicable
4	(i) Share Issuer:	Neurocrine Biosciences Inc
	(ii) Share:	The Neurocrine Biosciences Inc Shares
	(iii) ISIN:	US64125C1099
	(iv) Bloomberg Code:	NBIX UW Equity
	(v) Information Source:	<a href="https://www.nasdaq.com/">https://www.nasdaq.com/</a>
	(vi) Exchange:	NASDAQ
	(vii) Related Exchange:	All Exchanges
	(viii) Maximum Days of Disruption:	Eight Scheduled Trading Days as specified in Asset Term 1
	(ix) Adjustment basis for Share Basket and Reference Dates:	In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date and the Final Fixing Date: Share Basket and Reference Dates - Individual / Individual
	(x) Adjustment basis for Share Basket and Averaging Reference Dates:	Not Applicable
	(xi) Trade Date:	21 July 2021
	(xii) Jurisdictional Event:	Not Applicable
	(xiii) Jurisdictional Event Jurisdiction(s):	Not Applicable
	(xiv) Share Substitution:	Applicable
	(xv) Additional Disruption Events:	
	(a) Change in Law:	Change in Law Option 1 Applicable
	(b) Change of Exchange:	Applicable
	(c) Foreign Ownership Event:	Not Applicable
	(d) FX Disruption:	Not Applicable
	(e) Insolvency Filing:	Applicable
	(f) Hedging Disruption:	Applicable
	(g) Increased Cost of Hedging:	Not Applicable
	(h) Loss of Stock Borrow:	Not Applicable
	(i) Increased Cost of Stock Borrow:	Not Applicable
	(xvi) Dividend Adjusted Performance:	Not Applicable
56	Index-linked Securities:	Not Applicable
57	Commodity-linked Securities:	Not Applicable
58	Commodity Index-linked Securities:	Not Applicable
59	ETF-linked Securities:	Not Applicable

60	ETC-linked Securities:	Not Applicable
61	FX-linked Securities:	Not Applicable
62	FX Index-linked Securities:	Not Applicable
63	Inflation Index-linked Securities:	Not Applicable
64	Interest Rate Index-linked Securities:	Not Applicable
65	Cash Index-linked Securities:	Not Applicable
66	Multi-Asset Basket-linked Securities:	Not Applicable
67	Valuation Time:	As determined in accordance with Equity-linked Securities Asset Term 1

#### GENERAL PROVISIONS

68	(i) Form of Securities:	Bearer Securities
	(ii) Global Security:	Applicable
	(iii) NGN Form:	Not Applicable
	(iv) Intended to be held in a manner which would allow Eurosystem eligibility:	No. Whilst the designation is specified as "no" at the date of these Final Terms, should the Eurosystem eligibility criteria be amended in the future such that the Securities are capable of meeting them the Securities may then be deposited with one of the ICSDs as common safekeeper. Note that this does not necessarily mean that the Securities will then be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem at any time during their life. Such recognition will depend upon the European Central Bank being satisfied that Eurosystem eligibility criteria have been met.
	(v) The Issuer intends to permit indirect interests in the Securities to be held through CREST Depository Interests to be issued by the CREST Depository:	Not Applicable
69	Financial Centre(s):	Not Applicable
70	Business Centre(s):	Not Applicable
71	Listing and Admission to Trading:	Application will be made for the Securities to be listed on the Official List of the Luxembourg Stock Exchange and admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from on or around the Issue Date provided, however, no assurance can be given that such application for listing and admission to trading will be granted (or, if granted, will be granted by the Issue Date or any specific date thereafter)
72	Security Codes and Ticker Symbols:	
	ISIN:	XS2365553309
	Common Code:	236555330
	Swiss Security Number:	59954711
	Telekurs Ticker:	Not Applicable
	WKN Number:	Not Applicable
73	Clearing and Trading:	
	Clearing System(s) and any relevant identification number(s):	Euroclear Bank S.A./N.V. and Clearstream Banking, <i>société anonyme</i>
74	Delivery:	Delivery against payment
75	Agents:	
	Calculation Agent:	Credit Suisse International One Cabot Square London E14 4QJ United Kingdom
	Fiscal Agent:	The Bank of New York Mellon, acting through its London Branch One Canada Square London E14 5AL United Kingdom
	Paying Agent(s):	The Bank of New York Mellon, acting through its London Branch One Canada Square



		London E14 5AL United Kingdom
	Additional Agents:	Not Applicable
76	Dealer(s):	Credit Suisse International
77	Specified newspaper for the purposes of notices to Securityholders:	Not Applicable
78	871(m) Securities:	The Issuer has determined that the Securities (without regard to any other transactions) should not be treated as transactions that are subject to U.S. withholding tax under section 871(m)
79	Prohibition of Sales to EEA Retail Investors:	Applicable - see the cover page of these Final Terms
	Prohibition of Sales to UK Retail Investors:	Applicable - see the cover page of these Final Terms
80	Additional U.S. Tax Selling Restrictions:	Applicable – see "Additional U.S. Tax Selling Restrictions" under "United States", as set out in the section headed "Selling Restrictions"
81	Additional Provisions:	Not Applicable

## PART B - OTHER INFORMATION

### TERMS AND CONDITIONS OF THE OFFER

Not Applicable

### Fixed Rate Securities only - YIELD

Indication of yield:

An amount equal to 2.25% of the Nominal Amount in respect of each Interest Payment Date specified in paragraph 29(iii) above.

### INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

So far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the issue, save for any fees payable to the distributor(s).

The Securities will be sold by the Dealer to the distributor(s) at a discount of up to 6 per cent. of the Issue Price. Such discount represents the fee retained by the distributor(s) out of the Issue Price paid by investors

### PERFORMANCE OF SHARE/INDEX/COMMODITY/COMMODITY INDEX/ETF SHARE/ETC/FX RATE/FX INDEX/INFLATION INDEX/INTEREST RATE INDEX/CASH INDEX AND OTHER INFORMATION CONCERNING THE UNDERLYING ASSET(S)

Information on the Underlying Assets, including information about past and future performance as well as volatility, can be found free of charge on the following websites:

- (i) Sarepta Therapeutics Inc: <https://www.nasdaq.com>
- (ii) BioMarin Pharmaceutical Inc: <http://www.nasdaq.com>
- (iii) Vertex Pharmaceuticals Inc: <http://www.nasdaq.com>
- (iv) Neurocrine Biosciences Inc: <https://www.nasdaq.com/>

The information appearing on such websites does not form part of these Final Terms.

The Securities relate to a basket of Underlying Assets. The Securities have a "worst of" feature and therefore no weightings apply.

### POST-ISSUANCE INFORMATION

The Issuer will not provide any post-issuance information with respect to the Underlying Assets, unless required to do so by applicable law or regulation.

### REASONS FOR THE ISSUE, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

- (i) Reasons for the issue: See "Use of Proceeds" section in the Securities Note.
- (ii) Estimated net proceeds: USD 1,131,000.00
- (iii) Estimated total expenses: Not Applicable

Signed on behalf of the Issuer:

By:  \_\_\_\_\_

Julien Bieren  
Managing Director

Duly authorised

By:  \_\_\_\_\_  
Duly authorised

Yogamoorthy Logan  
Managing Director